heiDATA

Metrics

193,550 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

There was an error with your search parameters. Please clear your search and try again.

21 to 30 of 141 Results

Vardarli_Suppl Fig 41.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.2 KB - MD5: ad6c63c17fd489fa8c647b90891930e3 Suppl. Fig. 41. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 45.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 68.4 KB - MD5: d78f68109278d4cd9cce0b16cc721242 Suppl. Fig. 45. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 49.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 69.0 KB - MD5: 7a808d3c389b01b8f49293d6bfed88ab Suppl. Fig. 49. Funnel plot with trim-and-fill for trials investigating insulin-dependent diabetes mellitus any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 53.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 63.9 KB - MD5: a78f4750989043bac256c01eb6e1d727 Suppl. Fig. 53. Funnel plot with trim-and-fill for trials investigating insulin-dependent diabetes mellitus grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 10.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 219.1 KB - MD5: b0d44cc6d4f377511600f93c84adb67c Suppl. Table 10. Trim-and-fill results for trials investigating adrenal insufficiency grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 11.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 216.4 KB - MD5: 37c1389d7ef9b12de77e87300a627604 Suppl. Table 11. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 12.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 219.2 KB - MD5: f9d8e1df71b9731cc42906df4abab368 Suppl. Table 12. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 1.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 625.1 KB - MD5: 591d49eda306f69d5fd24a059d714ccc Suppl. Table 1. Checklist according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monoth...
Vardarli_Suppl. Table 2.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 363.9 KB - MD5: 7c1640658f8d06736e3dad712a927841 Suppl. Table 2. Search strategies for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors.
Vardarli_Suppl. Table 3.xlsx Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] MS Excel Spreadsheet - 116.7 KB - MD5: 7b97c14d958dffb9cb3347b48fd10fba Suppl. Table 3. Study characteristics of randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors. NSCLC, Non-small cell lung cancer; LD-SCLC, Limited...

Vardarli_Suppl Fig 41.pdf

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

Adobe PDF - 64.2 KB -

Suppl. Fig. 41. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 45.pdf

Adobe PDF - 68.4 KB -

Suppl. Fig. 45. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 49.pdf

Adobe PDF - 69.0 KB -

Suppl. Fig. 49. Funnel plot with trim-and-fill for trials investigating insulin-dependent diabetes mellitus any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 53.pdf

Adobe PDF - 63.9 KB -

Suppl. Fig. 53. Funnel plot with trim-and-fill for trials investigating insulin-dependent diabetes mellitus grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 10.pdf

Adobe PDF - 219.1 KB -

Suppl. Table 10. Trim-and-fill results for trials investigating adrenal insufficiency grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 11.pdf

Adobe PDF - 216.4 KB -

Suppl. Table 11. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 12.pdf

Adobe PDF - 219.2 KB -

Suppl. Table 12. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 1.pdf

Adobe PDF - 625.1 KB -

Suppl. Table 1. Checklist according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monoth...

Vardarli_Suppl. Table 2.pdf

Adobe PDF - 363.9 KB -

Suppl. Table 2. Search strategies for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors.

Vardarli_Suppl. Table 3.xlsx

MS Excel Spreadsheet - 116.7 KB -

Suppl. Table 3. Study characteristics of randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors. NSCLC, Non-small cell lung cancer; LD-SCLC, Limited...

Add Data

Share Dataverse

Link Dataverse

Reset Modifications